Tracey Regan

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

Two years after the FDA denied a request to expand the indication of finasteride and other 5α-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.

Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

Dr Jimmie C. Holland was long convinced that psychological status was a critical factor not just in cancer management, but in illness more broadly.

Oncologists too often fail to detect the severe distress that can accompany a diagnosis and subsequent treatment.

The Cancer Treatment Centers of America program will first be made available to patients with breast, colorectal, lung, and prostate cancers

The National Lung Screening Trial (NLST), a randomized, national trial involving 53,000 current and former heavy smokers, compared the effects of 2 screening procedures for lung cancer